Rhesus CXCL9 Protein
-
产品编号
KMP4303
-
别名
CXC 趋化因子配体9, CXCL9 Protein, Rhesus CXCL9 Protein
-
目录价格
联系客服获取报价RMB
-
规格
- 50ug
- 100ug
- 200ug
产品介绍
| Alias | CXC 趋化因子配体9, CXCL9 Protein, Rhesus CXCL9 Protein |
| Catalog Number | KMP4303 |
| Product Description | The Rhesus CXCL9 Protein(KMP4303) is produced in E. coli. A DNA sequence encoding the Rhesus CXCL9 (NP_001028108.1) (Thr23-Thr125) is expressed and purified with an initial Met. |
| Molecular Name | CXCL9 |
| Species | Rhesus |
| Host | E. coli |
| Size | 50ug, 100ug, 200ug |
| Protein Family | CD molecule |
| Purity | >95% as determined by SDS-PAGE |
| Concentration | 联系销售经理获得最新批次的浓度 |
| Purification | Affinity purification |
| Endotoxin | <1.0 EU/ug determined by the LAL method |
| Formulation | PBS, pH7.4 |
| Background | Chemokine (C-X-C motif) ligand 9 (CXCL9), also known as Monokine induced by gamma interferon (MIG), is a small cytokine belonging to the CXC chemokine family. The function of this chemokine has not been specifically defined; however, it is thought to be involved in T cell trafficking. CXCL9/MIG functions as one of the three ligands of chemokine receptor CXCR3 which is a G protein-coupled receptor found predominantly on T cells. CXCL9/MIG, together with CXCL10 and CXCL11, may activate CXCR3 by binding to it. CXCL9 serves as a cytokine that affects the growth, movement, or activation state of cells that participate in immune and inflammatory response. It has been observed that tumour endothelial cells secrete high levels of CXCL9 in all, and CXCL10 in most melanoma metastases. Experiment data represent novel mechanisms by which tumour cells in melanoma metastases might use the chemokine-expressing endothelium to leave the tumour and eventually to form additional metastases at distinct sites. Experiment results also improved that CXCL9/MIG plays an important role in CD4+ T lymphocyte recruitment and development of CAV, MOMA-2+ macrophages are the predominant recipient-derived source of CXCL9/MIG, and recipient CD4 lymphocytes are necessary for sustained CXCL9/MIG production and CAV development in this model. Neutralization of the chemokine CXCL9/MIG may have therapeutic potential for the treatment of chronic rejection after heart transplantation. |
| Application | WB, ELISA |
| Recommended Dilution | ELISA: 1:100-1:1000 |
| Cross-reactivity | No cross-reactivity with other antigens or proteins. |
| Predicted Molecular Weight | 11.9 kDa |
| Predicted N Terminus | Met |
| Reconstitution | Not applicable. The product is supplied as a ready-to-use liquid formulation. |
| Storage Condition | Aliquot and store at -20℃ to -80℃. Avoid repeated freezing and thawing cycles. |
| Remarks | 收到产品后请立即按保存条件储存；使用前短暂离心，使内容物集中于管底；避免反复冻融。 |
| Shipping Condition | In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. If supplied as liquid, the proteins will be shipped with dry ice. |
| Stability | Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
| Molecular Weight | 11.9 kDa |
| Cross-reactivity | No cross-reactivity with other antigens or proteins. |
| Note | 仅供科研使用 |
| ELISA IC50(ppb) | ≥ 1:1000 |
| Function | Chemokine (C-X-C motif) ligand 9 (CXCL9), also known as Monokine induced by gamma interferon (MIG), is a small cytokine belonging to the CXC chemokine family. The function of this chemokine has not been specifically defined; however, it is thought to be involved in T cell trafficking. CXCL9/MIG functions as one of the three ligands of chemokine receptor CXCR3 which is a G protein-coupled receptor found predominantly on T cells. CXCL9/MIG, together with CXCL10 and CXCL11, may activate CXCR3 by binding to it. CXCL9 serves as a cytokine that affects the growth, movement, or activation state of cells that participate in immune and inflammatory response. It has been observed that tumour endothelial cells secrete high levels of CXCL9 in all, and CXCL10 in most melanoma metastases. Experiment data represent novel mechanisms by which tumour cells in melanoma metastases might use the chemokine-expressing endothelium to leave the tumour and eventually to form additional metastases at distinct sites. Experiment results also improved that CXCL9/MIG plays an important role in CD4+ T lymphocyte recruitment and development of CAV, MOMA-2+ macrophages are the predominant recipient-derived source of CXCL9/MIG, and recipient CD4 lymphocytes are necessary for sustained CXCL9/MIG production and CAV development in this model. Neutralization of the chemokine CXCL9/MIG may have therapeutic potential for the treatment of chronic rejection after heart transplantation. |
| Product Declaration | 该产品仅供科研使用，不可直接用于人体或注射。 |
| Temperature Range | -20℃ ~ -80℃ |
| Solubility | 产品为即用型液体，无需复溶。 |
| Appearance | Liquid |
| Product Full Name | Rhesus CXCL9 Protein |
| Preservative Solution | PBS, pH7.4 |
| Usage Method | 冻干粉请按“复溶”说明用无菌去离子水复溶后使用，液体产品可直接使用；具体工作浓度请参考“推荐稀释比例”。 |
| Target | CXCL9 |
- 联系我们
- 电话：400-621-6806
- 手机：13116038708（微信）
- 邮箱：info@kmdbioscience.com
- 地址：天津市武清开发区和畅路6号10号厂房108室
-
销售微信
-
官方公众号
-
400-621-6806 -
3599163699 -
周一至周五 9:00-18:00 -
-
0
-
